CompletedPhase 3NCT04125836
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Studying Acromegaly
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Camurus AB
- Principal Investigator
- Diego Ferone, M.DUniversity of Genova Endocrinology Unit
- Intervention
- CAM2029 (octreotide subcutaneous depot)(drug)
- Enrollment
- 135 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2025
Study locations (30)
- UCLA Department of Medicine Division of Endocrinology, Los Angeles, California, United States
- Stanford University Medical Center, Palo Alto, California, United States
- Prufen Clinical Research LLC, Miami, Florida, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Washington University in St. Louis, School of Medicine, St Louis, Missouri, United States
- Palm Research Center, Las Vegas, Nevada, United States
- Columbia University Medical Center, New York, New York, United States
- University of Cincinnati, Cincinnati, Ohio, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- Allegheny Endocrinology Associates, Pittsburgh, Pennsylvania, United States
- Research Institute of Dallas, Dallas, Texas, United States
- Universitätsklinikum Essen, Essen, Germany
- Universitätsklinikum Frankfurt, Medizinische Klinik 1, Schwerpunkt Endokrinologie, Diabetologie, Ernährungsmedizin, Frankfurt, Germany
- Universitätsklinikum Freiburg, Freiburg im Breisgau, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04125836 on ClinicalTrials.govOther trials for Acromegaly
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT06930625A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin AnalogsDebiopharm International SA
- RECRUITINGPHASE2NCT07037420ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With AcromegalyAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT07179926Effects of Pasireotide Lar Therapy on Bone MetabolismFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE1NCT07195175Study of MAR002 in Healthy MenMarea Therapeutics
- RECRUITINGNCT06597383The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In AcromegalyIRCCS San Raffaele
- RECRUITINGNANCT06949891KETOgenic Diet Therapy in Patients With ACROmegalyErasmus Medical Center
- RECRUITINGNCT06344650Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.IRCCS San Raffaele
- RECRUITINGNCT05131100Korean Regulatory Post Marketing Surveillance for SomavertPfizer